NZ568168A - Methods for wound healing using ingenol compounds - Google Patents
Methods for wound healing using ingenol compoundsInfo
- Publication number
- NZ568168A NZ568168A NZ568168A NZ56816806A NZ568168A NZ 568168 A NZ568168 A NZ 568168A NZ 568168 A NZ568168 A NZ 568168A NZ 56816806 A NZ56816806 A NZ 56816806A NZ 568168 A NZ568168 A NZ 568168A
- Authority
- NZ
- New Zealand
- Prior art keywords
- euphorbia
- wound
- wounds
- pep005
- ingenol
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title description 43
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical class C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 title description 26
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 163
- 206010052428 Wound Diseases 0.000 claims abstract description 156
- 229960002993 ingenol mebutate Drugs 0.000 claims abstract description 116
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims abstract description 113
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims abstract description 113
- 231100000241 scar Toxicity 0.000 claims abstract description 22
- 230000001684 chronic effect Effects 0.000 claims abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 3
- 210000001519 tissue Anatomy 0.000 claims description 50
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000002847 Surgical Wound Diseases 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 206010011026 Corneal lesion Diseases 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 238000002266 amputation Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims 1
- 241000221079 Euphorbia <genus> Species 0.000 description 173
- -1 ingenol angelates Chemical class 0.000 description 105
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 76
- 210000002950 fibroblast Anatomy 0.000 description 75
- 230000002500 effect on skin Effects 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 48
- 102000004127 Cytokines Human genes 0.000 description 35
- 108090000695 Cytokines Proteins 0.000 description 35
- 239000000499 gel Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 27
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 25
- 210000002510 keratinocyte Anatomy 0.000 description 25
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 24
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 23
- 102000008186 Collagen Human genes 0.000 description 22
- 108010035532 Collagen Proteins 0.000 description 22
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 22
- 210000002744 extracellular matrix Anatomy 0.000 description 22
- 229920001436 collagen Polymers 0.000 description 21
- 239000001963 growth medium Substances 0.000 description 21
- 102000004889 Interleukin-6 Human genes 0.000 description 19
- 108090001005 Interleukin-6 Proteins 0.000 description 19
- 230000008569 process Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 13
- 230000008521 reorganization Effects 0.000 description 13
- 102000012422 Collagen Type I Human genes 0.000 description 12
- 108010022452 Collagen Type I Proteins 0.000 description 12
- 108090001007 Interleukin-8 Proteins 0.000 description 12
- 102000004890 Interleukin-8 Human genes 0.000 description 12
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 12
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000035876 healing Effects 0.000 description 11
- 230000037390 scarring Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 240000001837 Euphorbia peplus Species 0.000 description 9
- 108010067306 Fibronectins Proteins 0.000 description 9
- 102000016359 Fibronectins Human genes 0.000 description 9
- 230000016396 cytokine production Effects 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 244000067602 Chamaesyce hirta Species 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000221017 Euphorbiaceae Species 0.000 description 7
- 208000003367 Hypopigmentation Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 230000003810 hyperpigmentation Effects 0.000 description 7
- 208000000069 hyperpigmentation Diseases 0.000 description 7
- 230000003425 hypopigmentation Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 6
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 208000004210 Pressure Ulcer Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000002469 basement membrane Anatomy 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000036548 skin texture Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108700012920 TNF Proteins 0.000 description 4
- 208000009621 actinic keratosis Diseases 0.000 description 4
- 125000005601 angeloyl group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000001626 skin fibroblast Anatomy 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940042129 topical gel Drugs 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- UQOWJJGOQJONCI-UHFFFAOYSA-N 20-deoxyingenol-3-angelate Natural products CC1CC2C(C)(C)C2C2C=C(C)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O UQOWJJGOQJONCI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- UQOWJJGOQJONCI-MZRDIQIISA-N C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(C)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(C)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O UQOWJJGOQJONCI-MZRDIQIISA-N 0.000 description 3
- 206010011985 Decubitus ulcer Diseases 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 238000001303 quality assessment method Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241001448862 Croton Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000704053 Euphorbia lurida Species 0.000 description 2
- 241001553687 Euphorbia misella Species 0.000 description 2
- 241001553737 Euphorbia spathulata Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000558295 Homalanthus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Natural products N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004107 Penicillin G sodium Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000005905 alkynylation reaction Methods 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000008050 dialkyl sulfates Chemical class 0.000 description 2
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 2
- 229940008406 diethyl sulfate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 238000007804 gelatin zymography Methods 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000021995 interleukin-8 production Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000019369 penicillin G sodium Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000010388 wound contraction Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JHORJRSRQZDYPZ-UHFFFAOYSA-N 1,1,4,7,9-pentamethyldodecahydro-1h-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulene Chemical class CC1CC2C(C)(C)C2C2CC(C)CC3CC(C)CC31C2 JHORJRSRQZDYPZ-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 241001249944 Abbreviata Species 0.000 description 1
- 241001060350 Acalypha Species 0.000 description 1
- 241000933112 Acidoton Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001300714 Actinostemon Species 0.000 description 1
- 241001303063 Adelia <angiosperm> Species 0.000 description 1
- 241001303039 Adenocline Species 0.000 description 1
- 241001300216 Adenophaedra Species 0.000 description 1
- 241001554343 Agrostistachys Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241001554332 Alchornea Species 0.000 description 1
- 241001303001 Alchorneopsis Species 0.000 description 1
- 241000545417 Aleurites Species 0.000 description 1
- 241000867852 Amanoa Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001542137 Anacampseros Species 0.000 description 1
- 241000867911 Andrachne Species 0.000 description 1
- 235000015072 Antidesma Nutrition 0.000 description 1
- 241000785806 Antidesma Species 0.000 description 1
- 241001249101 Aporosa Species 0.000 description 1
- 241000310770 Argythamnia Species 0.000 description 1
- 241001300645 Astrococcus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001300062 Baliospermum Species 0.000 description 1
- 241000558349 Bernardia Species 0.000 description 1
- 240000005220 Bischofia javanica Species 0.000 description 1
- 235000010893 Bischofia javanica Nutrition 0.000 description 1
- 241001300032 Blachia Species 0.000 description 1
- 241001300698 Bonania Species 0.000 description 1
- 241000405421 Breynia Species 0.000 description 1
- 241000785605 Bridelia Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000071092 Candelabrum Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001300197 Caperonia Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001303011 Caryodendron Species 0.000 description 1
- 241000869021 Celianella Species 0.000 description 1
- 241001300690 Cephalocroton Species 0.000 description 1
- 241000366955 Chaenotheca Species 0.000 description 1
- 241000785810 Chaetocarpus Species 0.000 description 1
- 241000944318 Cheilosa Species 0.000 description 1
- 241001300185 Chiropetalum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000785597 Cleistanthus Species 0.000 description 1
- 241001300651 Cnesmone Species 0.000 description 1
- 241001300671 Cnidoscolus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000944184 Coccoceras Species 0.000 description 1
- 241000990192 Codiaeum Species 0.000 description 1
- 241000870753 Conceveiba Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000870724 Croizatia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241001300103 Crotonopsis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241001554488 Dalechampia Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000868948 Didymocistus Species 0.000 description 1
- 241000266013 Dimorphocalyx Species 0.000 description 1
- 241000867854 Discocarpus Species 0.000 description 1
- 241000819742 Ditaxis <mantid lacewing> Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241001060713 Drypetes Species 0.000 description 1
- 241000558350 Dysopsis Species 0.000 description 1
- 241001554477 Elateriospermum Species 0.000 description 1
- 241000558344 Endospermum Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000016998 Erismanthus Species 0.000 description 1
- 241001553302 Euphorbia aaron-rossii Species 0.000 description 1
- 241000704034 Euphorbia acerensis Species 0.000 description 1
- 241000116144 Euphorbia acuta Species 0.000 description 1
- 241001553293 Euphorbia alta Species 0.000 description 1
- 241001553159 Euphorbia angusta Species 0.000 description 1
- 241001373717 Euphorbia anthonyi Species 0.000 description 1
- 241001373703 Euphorbia arabica Species 0.000 description 1
- 241001373446 Euphorbia arizonica Species 0.000 description 1
- 241001191295 Euphorbia arteagae Species 0.000 description 1
- 241001082383 Euphorbia baselicis Species 0.000 description 1
- 241000704022 Euphorbia bergeri Species 0.000 description 1
- 241001553254 Euphorbia bicolor Species 0.000 description 1
- 241001553252 Euphorbia bifurcata Species 0.000 description 1
- 241001553250 Euphorbia bilobata Species 0.000 description 1
- 241001191291 Euphorbia brachiata Species 0.000 description 1
- 241000093820 Euphorbia brachycera Species 0.000 description 1
- 241001618844 Euphorbia caesia Species 0.000 description 1
- 241001553233 Euphorbia calcicola Species 0.000 description 1
- 241001373282 Euphorbia capitellata Species 0.000 description 1
- 241001373278 Euphorbia carmenensis Species 0.000 description 1
- 241001553150 Euphorbia carunculata Species 0.000 description 1
- 241001599902 Euphorbia celastroides Species 0.000 description 1
- 241001373713 Euphorbia chamaerrhodos Species 0.000 description 1
- 241000210641 Euphorbia chamaesula Species 0.000 description 1
- 241001373256 Euphorbia cinerascens Species 0.000 description 1
- 241001191285 Euphorbia colorata Species 0.000 description 1
- 241000093825 Euphorbia commutata Species 0.000 description 1
- 241000210643 Euphorbia creberrima Species 0.000 description 1
- 241000210644 Euphorbia crenulata Species 0.000 description 1
- 241001599887 Euphorbia cubensis Species 0.000 description 1
- 244000048459 Euphorbia cyathophora Species 0.000 description 1
- 241001553148 Euphorbia degeneri Species 0.000 description 1
- 241001373268 Euphorbia deltoidea Species 0.000 description 1
- 241001373244 Euphorbia dioeca Species 0.000 description 1
- 241000498739 Euphorbia dussii Species 0.000 description 1
- 241001553564 Euphorbia eanophylla Species 0.000 description 1
- 241001553561 Euphorbia eglandulosa Species 0.000 description 1
- 241001553555 Euphorbia eriantha Species 0.000 description 1
- 241000221085 Euphorbia esula Species 0.000 description 1
- 241001553525 Euphorbia exstipulata Species 0.000 description 1
- 241001373250 Euphorbia fendleri Species 0.000 description 1
- 241001373251 Euphorbia florida Species 0.000 description 1
- 241001373253 Euphorbia geyeri Species 0.000 description 1
- 241001373239 Euphorbia glyptosperma Species 0.000 description 1
- 241001373234 Euphorbia gracillima Species 0.000 description 1
- 241001553506 Euphorbia gradyi Species 0.000 description 1
- 241001553807 Euphorbia graminea Species 0.000 description 1
- 241001191151 Euphorbia guadalajarana Species 0.000 description 1
- 241001300734 Euphorbia guentheri Species 0.000 description 1
- 241001553803 Euphorbia hedyotoides Species 0.000 description 1
- 241000789809 Euphorbia helenae Species 0.000 description 1
- 241000210605 Euphorbia helleri Species 0.000 description 1
- 241001191145 Euphorbia hexagona Species 0.000 description 1
- 241001191128 Euphorbia hinkleyorum Species 0.000 description 1
- 241001373241 Euphorbia hooveri Species 0.000 description 1
- 241000072948 Euphorbia humistrata Species 0.000 description 1
- 244000106376 Euphorbia hypericifolia Species 0.000 description 1
- 241001553794 Euphorbia jaliscensis Species 0.000 description 1
- 241001373698 Euphorbia jejuna Species 0.000 description 1
- 241001553793 Euphorbia juttae Species 0.000 description 1
- 241000356166 Euphorbia knuthii Species 0.000 description 1
- 241001373338 Euphorbia lasiocarpa Species 0.000 description 1
- 241001373340 Euphorbia lata Species 0.000 description 1
- 241000498513 Euphorbia ledienii Species 0.000 description 1
- 241001373352 Euphorbia leucophylla Species 0.000 description 1
- 241001373354 Euphorbia linguiformis Species 0.000 description 1
- 241000355770 Euphorbia lugardae Species 0.000 description 1
- 241000817985 Euphorbia lupulina Species 0.000 description 1
- 241001191122 Euphorbia lycioides Species 0.000 description 1
- 241001191117 Euphorbia macropodoides Species 0.000 description 1
- 241001373324 Euphorbia mendezii Species 0.000 description 1
- 241001373326 Euphorbia mertonii Species 0.000 description 1
- 241001191114 Euphorbia mexiae Species 0.000 description 1
- 241001373328 Euphorbia micromera Species 0.000 description 1
- 241001373318 Euphorbia multiformis Species 0.000 description 1
- 241001600122 Euphorbia nutans Species 0.000 description 1
- 241001553675 Euphorbia oaxacana Species 0.000 description 1
- 241001373312 Euphorbia olowaluana Species 0.000 description 1
- 241001379530 Euphorbia parishii Species 0.000 description 1
- 241001373692 Euphorbia parryi Species 0.000 description 1
- 241001373304 Euphorbia pediculifera Species 0.000 description 1
- 241001373298 Euphorbia perlignea Species 0.000 description 1
- 241001373693 Euphorbia petrina Species 0.000 description 1
- 241001191102 Euphorbia pinetorum Species 0.000 description 1
- 241001373300 Euphorbia pionosperma Species 0.000 description 1
- 241001600106 Euphorbia poeppigii Species 0.000 description 1
- 241001373071 Euphorbia polycarpa Species 0.000 description 1
- 241001191099 Euphorbia polyphylla Species 0.000 description 1
- 241000704074 Euphorbia portulacoides Species 0.000 description 1
- 241000652460 Euphorbia procumbens Species 0.000 description 1
- 244000062608 Euphorbia prostrata Species 0.000 description 1
- 241001553778 Euphorbia pteroneura Species 0.000 description 1
- 241000704065 Euphorbia purpurea Species 0.000 description 1
- 241000097488 Euphorbia rapulum Species 0.000 description 1
- 241001373694 Euphorbia remyi Species 0.000 description 1
- 241001373069 Euphorbia revoluta Species 0.000 description 1
- 241001553755 Euphorbia robusta Species 0.000 description 1
- 241001177582 Euphorbia saxatilis Species 0.000 description 1
- 241000210614 Euphorbia schizoloba Species 0.000 description 1
- 241000704097 Euphorbia sclerocyathium Species 0.000 description 1
- 241001599919 Euphorbia sect. Cubanthus Species 0.000 description 1
- 241001553742 Euphorbia segoviensis Species 0.000 description 1
- 241001618891 Euphorbia seguieriana Species 0.000 description 1
- 241000244736 Euphorbia serpillifolia Species 0.000 description 1
- 241001373182 Euphorbia serrula Species 0.000 description 1
- 241001373183 Euphorbia setiloba Species 0.000 description 1
- 241001553558 Euphorbia sinclairiana Species 0.000 description 1
- 241001553739 Euphorbia sonorae Species 0.000 description 1
- 241001191091 Euphorbia soobyi Species 0.000 description 1
- 241001600080 Euphorbia stellata Species 0.000 description 1
- 241001553723 Euphorbia subpeltata Species 0.000 description 1
- 241001553722 Euphorbia succedanea Species 0.000 description 1
- 241000500281 Euphorbia telephioides Species 0.000 description 1
- 241000210615 Euphorbia tetrapora Species 0.000 description 1
- 244000256297 Euphorbia tirucalli Species 0.000 description 1
- 241001373689 Euphorbia trachysperma Species 0.000 description 1
- 241000210624 Euphorbia tuerckheimii Species 0.000 description 1
- 241001570576 Euphorbia turczaninowii Species 0.000 description 1
- 241000704100 Euphorbia umbellata Species 0.000 description 1
- 241001373162 Euphorbia umbellulata Species 0.000 description 1
- 241001373158 Euphorbia villifera Species 0.000 description 1
- 241001570573 Euphorbia whitei Species 0.000 description 1
- 241001191073 Euphorbia xanti Species 0.000 description 1
- 241000500277 Euphorbia xylopoda Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000789111 Excoecaria Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000785753 Flueggea Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241001300136 Gavarretia Species 0.000 description 1
- 241000221018 Gelonium Species 0.000 description 1
- 241001301420 Givotia Species 0.000 description 1
- 241000421432 Glochidion Species 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 241001303044 Glycydendron Species 0.000 description 1
- 241000608174 Gymnadenia Species 0.000 description 1
- 241001300749 Gymnanthes Species 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000869029 Hieronyma Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000868951 Hymenocardia Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 241000221089 Jatropha Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000870766 Lasiocroton Species 0.000 description 1
- 241001303065 Leucocroton Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001300746 Mabea Species 0.000 description 1
- 241001561070 Macaranga Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930184510 Mallotus Natural products 0.000 description 1
- 241001060384 Mallotus <angiosperm> Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 241000789133 Maprounea Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241000221024 Mercurialis Species 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 241000558300 Micrandra Species 0.000 description 1
- 241000404165 Microcephala Species 0.000 description 1
- 244000085338 Microdesmis Species 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 241001300738 Microstachys Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000558292 Neoscortechinia Species 0.000 description 1
- 241001639851 Nephradenia Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000870767 Omphalea Species 0.000 description 1
- 241001300642 Ophellantha Species 0.000 description 1
- 241001280335 Orbiculariae Species 0.000 description 1
- 241000558287 Ostodes Species 0.000 description 1
- 241000602295 Oxydectes Species 0.000 description 1
- 241000366197 Paludicola Species 0.000 description 1
- 241001300042 Pausandra Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001387976 Pera Species 0.000 description 1
- 241001387969 Petalostigma Species 0.000 description 1
- 241001130943 Phyllanthus <Aves> Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000789129 Pimelodendron Species 0.000 description 1
- 241000951867 Piranhea Species 0.000 description 1
- 241001300673 Platygyna Species 0.000 description 1
- 241001300677 Plukenetia Species 0.000 description 1
- 241000870720 Podocalyx Species 0.000 description 1
- 101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000014258 Polygonum bistorta Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001301608 Pycnocoma Species 0.000 description 1
- 241000867913 Reverchonia Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000867892 Richeria Species 0.000 description 1
- 241001333412 Richeriella Species 0.000 description 1
- 241000789127 Ricinocarpos Species 0.000 description 1
- 241000556257 Rupicola <angiosperm> Species 0.000 description 1
- 241001300086 Sagotia Species 0.000 description 1
- 241000994241 Sapium Species 0.000 description 1
- 244000057114 Sapium sebiferum Species 0.000 description 1
- 241000785917 Savia Species 0.000 description 1
- 244000078613 Scirpus geniculatus Species 0.000 description 1
- 241001301432 Sclerocroton Species 0.000 description 1
- 241000867909 Securinega Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040868 Skin hypopigmentation Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241001273190 Spathiostemon Species 0.000 description 1
- 241001354228 Spixia Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000789520 Strophioblachia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
- 241001300663 Tetraplandra Species 0.000 description 1
- 241000870728 Tetrorchidium Species 0.000 description 1
- 241001300199 Thyrsanthera Species 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 241000566916 Tomentella Species 0.000 description 1
- 241000870682 Trigonostemon Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000789056 Tyria Species 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- USAZACJQJDHAJH-KDEXOMDGSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-6-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](C=2NC(=O)NC(=O)C=2)O1 USAZACJQJDHAJH-KDEXOMDGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001889 chemoattractive effect Effects 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 235000005739 manihot Nutrition 0.000 description 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004346 phenylpentyl group Chemical group C1(=CC=CC=C1)CCCCC* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008215 regulation of wound healing Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229930187845 trigonostemon Natural products 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005906601A AU2005906601A0 (en) | 2005-11-25 | Therapeutic methods and compositions | |
| PCT/AU2006/001781 WO2007059584A1 (en) | 2005-11-25 | 2006-11-24 | Methods for wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ568168A true NZ568168A (en) | 2012-06-29 |
Family
ID=38066849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ568168A NZ568168A (en) | 2005-11-25 | 2006-11-24 | Methods for wound healing using ingenol compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090215884A1 (enExample) |
| EP (1) | EP1965818A4 (enExample) |
| JP (1) | JP2009517345A (enExample) |
| KR (1) | KR20080077625A (enExample) |
| CN (1) | CN101360506A (enExample) |
| BR (1) | BRPI0618926A2 (enExample) |
| CA (1) | CA2629899A1 (enExample) |
| NZ (1) | NZ568168A (enExample) |
| WO (1) | WO2007059584A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ801700A0 (en) | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| NZ583157A (en) | 2004-12-13 | 2011-12-22 | Leo Lab Ltd | Treatment of solid cancers with angeloyl substituted ingenanes |
| JP5291369B2 (ja) * | 2008-03-31 | 2013-09-18 | 株式会社ナリス化粧品 | ケラチノサイト増殖促進剤 |
| CA2752389C (en) * | 2009-02-13 | 2017-01-03 | Peplin Research Pty Ltd | Use of ingenols in the treatment of aged skin |
| KR101769294B1 (ko) | 2009-08-26 | 2017-08-18 | 마리 케이 인코포레이티드 | 식물 추출물을 포함하는 국소 피부 케어 제형 |
| HUE034138T2 (en) | 2010-04-16 | 2018-01-29 | Leo Pharma As | Orthopedic crystalline ingenol mebuta |
| MX2012013787A (es) * | 2010-06-30 | 2012-12-17 | Avon Prod Inc | Composiciones y metodos para estimular magp-1 y mejorar la apariencia de la piel. |
| US9402823B2 (en) | 2010-12-17 | 2016-08-02 | Leo Laboratories Limited | Ingenols for treating seborrheic keratosis |
| TWI591047B (zh) * | 2010-12-22 | 2017-07-11 | 理奧實驗有限公司 | 巨大戟萜醇-3-醯化物iii及巨大戟萜醇-3-胺基甲酸酯化物 |
| BR112013015859A2 (pt) * | 2010-12-22 | 2018-11-21 | Leo Laboratories Ltd | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica |
| EP2655311A1 (en) | 2010-12-22 | 2013-10-30 | Leo Laboratories Limited | Ingenol-3-acylates i |
| GB201110777D0 (en) | 2011-06-24 | 2011-08-10 | Aqua Bio Technology Asa | Methods and uses |
| WO2012176015A1 (en) * | 2011-06-24 | 2012-12-27 | Leo Pharma A/S | Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate |
| US20140348905A1 (en) * | 2011-12-12 | 2014-11-27 | Leo Laboratories Limited | Gel compositions |
| US20130251782A1 (en) * | 2012-03-22 | 2013-09-26 | Leo Laboratories Limited | Topical application of ingenol mebutate with occlusion |
| JP6216781B2 (ja) * | 2012-06-26 | 2017-10-18 | レオ・ラボラトリーズ・リミテッドLeo Laboratories Limited | 3−o−ヘテロアリール−インゲノール |
| AU2013285409B2 (en) * | 2012-07-06 | 2018-03-15 | Leo Pharma A/S | A topical composition comprising a film-forming polymer for delivering an active ingredient to skin |
| US9962364B2 (en) | 2012-12-26 | 2018-05-08 | A-Z Ltd. | Wound healing accelerator |
| WO2014158858A1 (en) * | 2013-03-13 | 2014-10-02 | Avon Products, Inc | Glochidium wallichianum extracts and methods of use |
| CN105055448A (zh) * | 2015-05-25 | 2015-11-18 | 中国人民解放军第三军医大学第一附属医院 | 铜离子制剂在制备促进皮肤角质形成细胞增殖药物或敷料中的用途 |
| EP3429609B9 (en) * | 2016-03-18 | 2023-08-16 | Precigen, Inc. | Compositions and methods for treatment of type vii collagen deficiencies |
| CN106619600B (zh) * | 2016-03-28 | 2019-10-18 | 中国科学院遗传与发育生物学研究所 | 巨大戟醇及其衍生物在增强溶酶体生成中的应用 |
| CN115677520B (zh) * | 2022-11-18 | 2024-04-02 | 扬州大学 | 一种二萜化合物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809749A (en) * | 1971-03-05 | 1974-05-07 | Amazon Natural Drug Co | Topical pharmaceutical composition and method employing sap from the tree croton lechleri |
| DE2902506A1 (de) * | 1979-01-23 | 1980-07-24 | Deutsches Krebsforsch | Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel |
| US4418064A (en) * | 1982-09-29 | 1983-11-29 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone |
| US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| US5891870A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US5962498A (en) * | 1986-06-11 | 1999-10-05 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity |
| US5716968A (en) * | 1986-06-11 | 1998-02-10 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. H. |
| US5145842A (en) * | 1986-06-11 | 1992-09-08 | Alder Research Center Limited Partnership | Protein kinase c. modulators. d. |
| US5643948A (en) * | 1986-06-11 | 1997-07-01 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. K. |
| US5891906A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
| US5886019A (en) * | 1986-06-11 | 1999-03-23 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. F. |
| US5886017A (en) * | 1986-06-11 | 1999-03-23 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. E. |
| US5750568A (en) * | 1986-06-11 | 1998-05-12 | Procyon Pharmaceuticals, Inc. | Protein kinase C Modulators. L. |
| DE4102054A1 (de) * | 1991-01-24 | 1992-07-30 | Geb Szenasi Tamas | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe |
| US5863938A (en) * | 1991-03-01 | 1999-01-26 | Warner Lambert Company | Antibacterial-wound healing compositions and methods for preparing and using same |
| US5317009A (en) * | 1991-08-26 | 1994-05-31 | New York University | Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof |
| US6593371B1 (en) * | 1993-05-19 | 2003-07-15 | Jeff J. Staggs | Treatment for wart and related disorders |
| US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
| US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
| AUPO864097A0 (en) | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
| ES2174550T3 (es) * | 1999-01-29 | 2002-11-01 | Sid Soc Ind De La Doux S A | Dispositivo triturador con al menos un eje rotatorio. |
| CA2380805C (en) * | 1999-08-13 | 2010-04-13 | Photogen, Inc. | Improved topical medicaments and methods for photodynamic treatment of disease |
| JP2001139468A (ja) * | 1999-11-11 | 2001-05-22 | Lead Chemical Co Ltd | 抗ウイルス作用を有するホルボール誘導体 |
| AUPQ801700A0 (en) * | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| AUPQ923100A0 (en) * | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
| US6923993B2 (en) * | 2001-12-12 | 2005-08-02 | Nicholas J. Donato | Process of isolating extract from the Euphorbia obesa plant and methods for using the same |
| US7390499B2 (en) * | 2002-04-26 | 2008-06-24 | Lohmann & Rauscher Gmbh | Microbial cellulose wound dressing for treating chronic wounds |
| US7939090B2 (en) * | 2003-10-21 | 2011-05-10 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| DK1628673T3 (da) * | 2004-01-01 | 2007-06-18 | Panacea Biotec Ltd | Farmaceutiske sammensætninger, der omfatter en ekstrakt af Euphorbia prostrata |
| BRPI0504797B1 (pt) * | 2005-10-27 | 2020-02-04 | Pele Nova Biotecnologia S.A. | formulação tópica, método de tratamento cosmético para rejuvenescimento da pele, método de tratamento cosmético e uso de uma formulação |
-
2006
- 2006-11-24 NZ NZ568168A patent/NZ568168A/en not_active IP Right Cessation
- 2006-11-24 WO PCT/AU2006/001781 patent/WO2007059584A1/en not_active Ceased
- 2006-11-24 CA CA002629899A patent/CA2629899A1/en not_active Abandoned
- 2006-11-24 BR BRPI0618926-1A patent/BRPI0618926A2/pt not_active IP Right Cessation
- 2006-11-24 KR KR1020087014376A patent/KR20080077625A/ko not_active Ceased
- 2006-11-24 US US12/094,713 patent/US20090215884A1/en not_active Abandoned
- 2006-11-24 EP EP06817537A patent/EP1965818A4/en not_active Withdrawn
- 2006-11-24 CN CNA2006800516339A patent/CN101360506A/zh active Pending
- 2006-11-24 JP JP2008541550A patent/JP2009517345A/ja active Pending
-
2016
- 2016-04-18 US US15/131,851 patent/US20160317486A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160317486A1 (en) | 2016-11-03 |
| EP1965818A1 (en) | 2008-09-10 |
| EP1965818A4 (en) | 2010-02-17 |
| WO2007059584A1 (en) | 2007-05-31 |
| KR20080077625A (ko) | 2008-08-25 |
| BRPI0618926A2 (pt) | 2011-09-13 |
| CN101360506A (zh) | 2009-02-04 |
| JP2009517345A (ja) | 2009-04-30 |
| US20090215884A1 (en) | 2009-08-27 |
| CA2629899A1 (en) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160317486A1 (en) | Method for wound healing | |
| RU2506951C2 (ru) | Лечение повреждений, индуцированных вирусом | |
| Cherniack | Bugs as Drugs, Part 1: Insects: the" new" alternative medicine for the 21st century | |
| Xie et al. | Gastroprotective effect of gamma-aminobutyric acid against ethanol-induced gastric mucosal injury | |
| KR20150040909A (ko) | 피부 아토피의 화장품 치료에서 수크로오스 스테아레이트 및/또는 소르비탄 에스터에 의한 병원성 미생물의 부착 억제 | |
| US8835496B2 (en) | Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride for treating of skin, mucosa, hair, nails, or scalp | |
| UA76415C2 (uk) | Застосування похідних бігуаніду для отримання лікарського препарату з ефектом загоєння ран | |
| Sedik et al. | Cold plasma approach fortifies the topical application of thymoquinone intended for wound healing via up-regulating the levels of TGF-ß, VEGF, and α-SMA in rats | |
| JP2013060455A (ja) | ハチ毒を有効成分とする組成物 | |
| Rahayu et al. | Effectiveness of black soldier fly (Hermetia illucens) prepupa oil emulgel for burn wound recovery | |
| WO2018143692A1 (ko) | 유근피 또는 유백피 파우더를 유효성분으로 포함하는 창상 치료 및 피부 재생용 약학 조성물 | |
| KR101799300B1 (ko) | Clasp2를 이용한 상처 치유 또는 피부 재생용 조성물 | |
| AU2006317523A1 (en) | Methods for wound healing | |
| CN118319920A (zh) | 蒲公英甾醇或其盐在制备预防或治疗脓毒性脑损伤药物中的应用 | |
| KR20210066660A (ko) | 흑찰거대배아미 추출물을 포함하는 항염, 피부 보습용, 피부 상처 치유용, 또는 피부 재생 촉진용 조성물 | |
| US20200390841A1 (en) | Compositions and methods for treating wounds | |
| US11439655B2 (en) | Compounds for use in wound healing and angiogenesis | |
| Mohi-Eldin et al. | Clinical and pathological assessment of aloe vera and propolis for wound healing in normal and diabetic albino rats | |
| HRP20100108A2 (hr) | Upotreba ramnolipida kao lijeka izbora u slučaju nuklearnih katastrofa za liječenje kombiniranih radijacijskih ozljeda i bolesti u ljudi i životinja | |
| CZ305405B6 (cs) | Použití kombinace obsahující polymerové absorpční činidlo a nemetabolizovatelný cukr pro podporu buněčné rekonstrukce a/nebo buněčné diferenciace | |
| US5994399A (en) | Method of regenerating collagen-containing tissues with misoprostol | |
| KR102605184B1 (ko) | 동백화밀을 포함하는 항노화용 조성물 | |
| KR20200124570A (ko) | 용아초 추출물을 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물 | |
| KR20200122868A (ko) | 대계 추출물을 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물 | |
| KR20170061084A (ko) | 휴매닌 또는 이의 유사체를 유효성분으로 함유하는 창상 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: LEO LABORATORIES LIMITED, IE Free format text: OLD OWNER(S): PEPLIN RESEARCH PTY LTD |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |